BiotechTube

INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil

Phase 1Recruiting
1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ewing Sarcoma

Conditions

Ewing Sarcoma

Trial Timeline

Oct 8, 2018 → Dec 1, 2026

NCT ID
NCT03715933

About INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil

INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil is a phase 1 stage product being developed by Inhibrx Biosciences for Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03715933. Target conditions include Ewing Sarcoma.

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03715933Phase 1Recruiting

Competing Products

14 competing products in Ewing Sarcoma

See all competitors
ProductCompanyStageHype Score
LinsitinibAstellas PharmaPhase 2
35
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
42
Abemaciclib + Irinotecan + TemozolomideEli LillyPhase 2
39
IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab)Eli LillyPhase 2
35
XaluritamigAmgenPhase 1
36
CP-751,871PfizerPhase 1
29
CP-751,871PfizerPhase 1/2
32
Palbociclib + Temozolomide + Irinotecan + Topotecan + CyclophosphamidePfizerPhase 2
39
plerixafor + plerixafor + plerixaforSanofiPhase 1/2
32
regorafenib tabletBayerPhase 1
30
INCB059872IncytePhase 1
18
LurbinectedinJazz PharmaceuticalsPhase 1/2
36
LurbinectedinJazz PharmaceuticalsPhase 1/2
36
CabozantinibExelixisPhase 1
33